CD HEALTH ALERT: Oral Agents for the Treatment of COVID-19

CD News Alert

December 27, 2021

The Food and Drug Administration (FDA) last week issued emergency use authorizations (EUA) for the use of Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use), and Merck’s Molnupiravir, for treatment of COVID-19.

Patients eligible for treatment with Paxlovid or Molnupiravir are those who have mild-to-moderate COVID-19 and are at high risk for progression to severe disease.